ELEKTA AB-B SHS-UNSPON ADR Business Summary

Elekta AB (EKTAY) is a global leader in precision radiation medicine, generating revenue through the sale of advanced radiotherapy hardware, oncology informatics software, and high-margin recurring service contracts, which account for nearly half of total turnover. The company operates through three primary segments: Oncology Treatment Solutions (linear accelerators like Versa HD and Elekta Unity), Neuro Solutions (the Leksell Gamma Knife), and Brachytherapy. Elekta is currently executing its "Must-Win Battles" strategy, focusing on AI-driven adaptive radiotherapy and expanding its software-as-a-service (SaaS) offerings following the 2024 acquisition of MIM Software. In the competitive landscape, Elekta maintains the second-largest global market share behind Varian Medical Systems (a Siemens Healthineers company), while competing directly with Accuray, RaySearch Laboratories, and United Imaging; it differentiates itself through its unique MRI-guided linear accelerator technology and a dominant position in stereotactic radiosurgery. The company was founded in 1972 by Lars Leksell, the pioneer of radiosurgery, and remains under the strategic guidance of the Leksell family, with Laurent Leksell serving as Chairman of the Board. The executive leadership is headed by President and CEO Jakob Just-Bomholt, who took office in September 2025 to lead a major organizational restructuring and profitability drive. He is supported by CFO Klara Eiritz, who joined in early 2026, and Christopher Busch, the Chief Product and Technology Officer. The board includes notable figures such as Caroline Leksell Cooke and Jan Secher. Major institutional backing is provided by the Leksell family’s holding companies, alongside significant positions held by Swedish pension funds and international asset managers like BlackRock and Vanguard, reflecting its status as a cornerstone of the Nordic medtech sector.